Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
87,000
-400 (-0.46%)
At close: Dec 5, 2025
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 429.82B KRW in the quarter ending September 30, 2025, with 4.13% growth. This brings the company's revenue in the last twelve months to 1.68T, up 0.32% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.
Revenue (ttm)
1,680.99B
Revenue Growth
+0.32%
P/S Ratio
0.68
Revenue / Employee
746.11M
Employees
2,253
Market Cap
1,146.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,586.43B | -82.97B | -4.97% |
| Dec 31, 2023 | 1,669.40B | 181.06B | 12.17% |
| Dec 31, 2022 | 1,488.34B | 144.79B | 10.78% |
| Dec 31, 2021 | 1,343.56B | 40.55B | 3.11% |
| Dec 31, 2020 | 1,303.01B | 223.67B | 20.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |